Real-time Estimate
Cboe BZX
11:20:04 2024-05-23 am EDT
|
5-day change
|
1st Jan Change
|
53.87
USD
|
-0.72%
|
|
+2.03%
|
-2.95%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,359
|
2,882
|
2,903
|
-
|
-
|
Enterprise Value (EV)
1 |
1,104
|
2,180
|
2,274
|
2,372
|
1,958
|
P/E ratio
|
-5.97
x
|
-37.8
x
|
-28.7
x
|
-26.1
x
|
-23.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
26.1
x
|
30.4
x
|
29.4
x
|
27.1
x
|
EV / Revenue
|
-
|
19.8
x
|
23.8
x
|
24.1
x
|
18.3
x
|
EV / EBITDA
|
-5.81
x
|
-24.8
x
|
-45.8
x
|
-18
x
|
-12.7
x
|
EV / FCF
|
-10.9
x
|
11.7
x
|
-36
x
|
-28.2
x
|
-51.2
x
|
FCF Yield
|
-9.2%
|
8.54%
|
-2.78%
|
-3.54%
|
-1.95%
|
Price to Book
|
-
|
5.98
x
|
4.36
x
|
4.54
x
|
3.58
x
|
Nbr of stocks (in thousands)
|
43,854
|
51,929
|
53,503
|
-
|
-
|
Reference price
2 |
30.98
|
55.50
|
54.26
|
54.26
|
54.26
|
Announcement Date
|
3/29/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
110.3
|
95.61
|
98.59
|
107.1
|
EBITDA
1 |
-
|
-63.98
|
-189.9
|
-87.84
|
-49.63
|
-131.7
|
-153.9
|
EBIT
1 |
-
|
-65.02
|
-191.3
|
-89.88
|
-115.1
|
-154.3
|
-152.1
|
Operating Margin
|
-
|
-
|
-
|
-81.47%
|
-120.36%
|
-156.53%
|
-142.01%
|
Earnings before Tax (EBT)
1 |
-32.1
|
-
|
-188.7
|
-70.03
|
-102
|
-139.2
|
-132.2
|
Net income
1 |
-32.1
|
-64.97
|
-188.7
|
-70.69
|
-97.47
|
-126
|
-124.8
|
Net margin
|
-
|
-
|
-
|
-64.08%
|
-101.94%
|
-127.83%
|
-116.55%
|
EPS
2 |
-
|
-145.6
|
-5.190
|
-1.470
|
-1.889
|
-2.081
|
-2.284
|
Free Cash Flow
1 |
-
|
-
|
-101.6
|
186.1
|
-63.2
|
-84.06
|
-38.25
|
FCF margin
|
-
|
-
|
-
|
168.73%
|
-66.1%
|
-85.27%
|
-35.72%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/14/22
|
3/24/22
|
3/29/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
17.91
|
14.3
|
14.96
|
63.15
|
39.26
|
19.37
|
19.82
|
18.62
|
15.11
|
15.11
|
EBITDA
|
-
|
-
|
-32.46
|
-93.54
|
-39.59
|
-30.02
|
-29.06
|
-44.42
|
15.72
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.7
|
-32.44
|
-32.61
|
-93.88
|
-40
|
-30.46
|
-29.56
|
-44.86
|
15
|
-15.81
|
-35.86
|
-38.5
|
-40.86
|
-47.81
|
-49.77
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-170.04%
|
-206.68%
|
-299.94%
|
23.75%
|
-40.27%
|
-185.15%
|
-194.21%
|
-219.46%
|
-316.34%
|
-329.26%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-32.09
|
-92.87
|
-38.99
|
-27.02
|
-24.14
|
-39.34
|
20.47
|
-7.198
|
-31.2
|
-33.95
|
-38.02
|
-43.61
|
-45.56
|
Net income
1 |
-20.67
|
-32.38
|
-32.09
|
-92.87
|
-38.99
|
-27.34
|
-23.85
|
-39.34
|
19.84
|
-7.198
|
-31.22
|
-33.98
|
-38.06
|
-43.61
|
-45.56
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-152.66%
|
-166.79%
|
-262.99%
|
31.42%
|
-18.34%
|
-161.17%
|
-171.42%
|
-204.41%
|
-288.52%
|
-301.45%
|
EPS
2 |
-39.85
|
-1.560
|
-0.8800
|
-2.120
|
-0.7600
|
-0.5800
|
-0.5000
|
-0.8100
|
0.4200
|
-0.1400
|
-0.5800
|
-0.6400
|
-0.6956
|
-0.7180
|
-0.7140
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/29/23
|
5/8/23
|
8/14/23
|
11/13/23
|
2/28/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
255
|
702
|
629
|
531
|
945
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-102
|
186
|
-63.2
|
-84.1
|
-38.3
|
ROE (net income / shareholders' equity)
|
-
|
-80%
|
-452%
|
-20.5%
|
-3.92%
|
-18.1%
|
-13.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
9.280
|
12.40
|
12.00
|
15.10
|
Cash Flow per Share
2 |
-
|
-122.0
|
-2.730
|
4.320
|
-0.7900
|
1.730
|
-
|
Capex
1 |
-
|
5.78
|
2.28
|
21.4
|
9.01
|
9.92
|
14.3
|
Capex / Sales
|
-
|
-
|
-
|
19.42%
|
9.42%
|
10.06%
|
13.35%
|
Announcement Date
|
1/14/22
|
3/24/22
|
3/29/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
54.26
USD Average target price
80.57
USD Spread / Average Target +48.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.95% | 2.9B | | +63.28% | 62.59B | | -2.14% | 41.18B | | +44.19% | 40.29B | | -8.29% | 27.9B | | +11.99% | 26.21B | | -21.88% | 19.09B | | +5.05% | 13.08B | | +25.22% | 12.26B | | +28.03% | 12.05B |
Other Biotechnology & Medical Research
|